HomeGILD • NASDAQ
Gilead Sciences, Inc.
$62.86
After Hours:
$62.86
(0.00%)0.00
Closed: Sep 23, 4:22:42 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$63.77
Day range
$62.30 - $63.79
Year range
$57.17 - $74.12
Market cap
78.79B USD
Avg Volume
7.38M
P/E ratio
19.17
Dividend yield
4.65%
Primary exchange
NASDAQ
CDP Climate Change Score
B
Financials
Income Statement
Revenue
Net income
(USD)Jun 2022Y/Y change
Revenue
6.26B0.69%
Operating expense
2.46B0.61%
Net income
1.14B-24.84%
Net profit margin
18.27-25.37%
Earnings per share
1.58-15.51%
EBITDA
2.88B-0.62%
Effective tax rate
24.48%
Total assets
Total liabilities
(USD)Jun 2022Y/Y change
Cash and short-term investments
6.14B-10.29%
Total assets
62.87B-7.52%
Total liabilities
42.66B-11.64%
Total equity
20.22B
Shares outstanding
1.25B
Price to book
3.95
Return on assets
9.36%
Return on capital
12.74%
Net change in cash
(USD)Jun 2022Y/Y change
Net income
1.14B-24.84%
Cash from operations
1.80B-22.19%
Cash from investing
-308.00M46.62%
Cash from financing
-1.00B-7.73%
Net change in cash
443.00M-46.50%
Free cash flow
1.95B-1.13%
About
Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligomers, small strands of DNA used to target genetic sequences. Gilead held its IPO in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s, but came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Founded
Jun 22, 1987
Website
Employees
14,400
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for